Product Portfolio header Spectrum Pharmaceuticals Product Portfolio picture
   
Oncology, Generics, Neurology Drugs About Spectrum Pharmaceuticals SPPI Investor Relations SPPI News
shadow area

SPI-392


Target Indications
  • Schizophrenia

Route of Administration
  • Oral

SPI-392 Status
  • Preclinical

SPI-392 Activity Profile

In animal studies to date:
  • Reverses phencyclidine-induced disruption of pre-pulse inhibition (psychosis model)
  • Disrupts conditioned avoidance responding (cognition model)
  • Novel receptor profile as compared to the currently available antipsychotics
  • Data suggests that this compound is a D4-dopaminergic receptor antagonist and a 5-HT1A-serotonergic receptor agonist
  • Good safety profile and therapeutic index
SPI-392

Schizophrenia Market

An estimated 2 million Americans or 1% of the American population is affected by schizophrenia. Both men and women are affected in equal numbers, although onset is slightly later in women. People with schizophrenia suffer severe disturbances in thinking, social and emotions such as hearing internal voices not heard by others, or believing that other people are reading their minds, controlling their thoughts or plotting to harm them.

While there are available treatments that can relieve some of the symptoms, these medications cause significant side effects such as involuntary motor activity, weight gain, and social withdrawal.

SPI-392 is available for outlicensing.

back to top

Advanced Search  |  Home  |  Site Map  |  Contact Us  |  WebMail

 All contents © Copyright Spectrum Pharmaceuticals, Inc. 2008. All Rights Reserved.  Terms of Use

y>